Disclosed positions

Estimated from their latest filings — positions may have changed since

$31.85M

combined est. value

Stock	Shares	Price	Value	Weight	As of
VRTXVERTEX PHARMACEUTICALS INC / MA	63,368	$464.62	$29.44M	92%	2025-07-01
RYTMRHYTHM PHARMACEUTICALS, INC.	11,712	$114.43	$1.34M	4%	2026-06-23
PRAXPraxis Precision Medicines, Inc.	2,537	$337.25	$855.6K	3%	2026-06-10
ALNYALNYLAM PHARMACEUTICALS, INC.	671	$313.04	$210.0K	1%	2026-05-20

VRTX

VERTEX PHARMACEUTICALS INC / MA

$29.44M

63,368 sh

RYTM

RHYTHM PHARMACEUTICALS, INC.

$1.34M

11,712 sh

PRAX

Praxis Precision Medicines, Inc.

$855.6K

2,537 sh

ALNY

ALNYLAM PHARMACEUTICALS, INC.

$210.0K

671 sh

All filings on record

Every Form 4 transaction we track for this filer

all 7buys 0sells 0

Stock	Transaction	Date	~6mo later
RYTMRHYTHM PHARMACEUTICALS, INC.	Exercise — · 4,712 sh	2026-06-23	—
PRAXPraxis Precision Medicines, Inc.	Grant — · 1,371 sh	2026-06-10	—
ALNYALNYLAM PHARMACEUTICALS, INC.	Grant — · 671 sh	2026-05-20	—
PRAXPraxis Precision Medicines, Inc.	Grant — · 478 sh	2026-02-06	—
PRAXPraxis Precision Medicines, Inc.	Grant — · 688 sh	2026-02-06	—
VRTXVERTEX PHARMACEUTICALS INC / MA	Tax $16.77M · 37,243 sh	2025-07-01	—
RYTMRHYTHM PHARMACEUTICALS, INC.	Exercise — · 4,000 sh	2025-06-18	—

RYTMExercise

2026-06-23 · RHYTHM PHARMACEUTICALS, INC.

4,712

—

PRAXGrant

2026-06-10 · Praxis Precision Medicines, Inc.

1,371

—

ALNYGrant

2026-05-20 · ALNYLAM PHARMACEUTICALS, INC.

671

—

PRAXGrant

2026-02-06 · Praxis Precision Medicines, Inc.

478

—

PRAXGrant

2026-02-06 · Praxis Precision Medicines, Inc.

688

—

VRTXTax

2025-07-01 · VERTEX PHARMACEUTICALS INC / MA

$16.77M

—

RYTMExercise

2025-06-18 · RHYTHM PHARMACEUTICALS, INC.

4,000

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.